BLVIS A Blue Vision A

Completion of subscription of convertible loans

Completion of subscription of convertible loans

25 January 2024

Company Announcement No. 03



Completion of subscription of convertible loans

On 22 January 2024 the Board of Directors in Pharma Equity Group decided to issue convertible loans in accordance with the authorisation in the company's articles of association under article 4.3.A.

The convertible loans are now fully subscribed for and allow Pharma Equity Group to loan DKK 8.914.795, which has now been paid out to the company. Thus, the maximum increase of the share capital pursuant to the convertible loan is an amount of DKK 12.627.691.

The main terms are described in the company’s articles of association and Company Announcement no. 01, dated 22 January 2024.

The Board of Directors will inform the market about conversion of the convertible debt.



For further information, please contact:

Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone:

Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone:



About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.

Attachment



EN
25/01/2024

Underlying

BLVIS ABlue Vision A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Forløb af generalforsamlingen i Pharma Equity Group A/S

Forløb af generalforsamlingen i Pharma Equity Group A/S      Forløb af generalforsamlingen i Pharma Equity Group A/S  05. maj 2025Selskabsmeddelelse nr. 6 Pharma Equity Group A/S har 16 april 2025 afholdt ordinær generalforsamling med følgende resultat:  Dirigenten gennemgik dagsordenen for dagens generalforsamling, som var: Bestyrelsens beretning om Selskabets virksomhed det forløbne årFremlæggelse af revideret årsrapport til godkendelseMeddelelse af decharge for bestyrelsen og direktionenVedtagelse af fordeling af overskud eller underskud efter forslag fra bestyrelsenFremlæggelse af v...

May 5, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Passing of the General Meeting of Pharma Equity Group A/S

Passing of the General Meeting of Pharma Equity Group A/S      Passing of the General Meeting of Pharma Equity Group A/S  5th of May 2025Company Announcement no. 6 Pharma Equity Group A/S held its Annual General Meeting on 16th of April 2025 with the following results:   The chairman of the meeting reviewed the agenda for today's general meeting, which was: The Board of Directors’ report on the Company’s activities during the past yearPresentation of the audited annual report for approvalDischarge of the Board of Directors and Executive ManagementAdoption of the a...

May 5, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Bestyrelsens beslutning om udstedelse af konvertible lån

Bestyrelsens beslutning om udstedelse af konvertible lån       Bestyrelsens beslutning om udstedelse af konvertible lån  1. april 2025Meddelelse nr. 4   Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af konvertible lån i henhold til bemyndigelsen i selskabets vedtægter under pkt. 4.3.A. De konvertible lån giver Pharma Equity Group mulighed for at låne op til DKK 6.757.895. Hovedvilkårene for de konvertible lån er:  Lånene er ydet som ansvarlig lånekapital og er således efterstillet selskabets øvrige kreditorer, bortset fra eventuel anden tilsvarende an...

April 1, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

The Board of Directors' resolution on the issuance of convertible loan...

The Board of Directors' resolution on the issuance of convertible loans      The Board of Directors' resolution on the issuance of convertible loans  April 1, 2025Announcement no. 4 The Board of Directors of Pharma Equity Group has decided to issue convertible loans in accordance with the authorisation in the Company's Articles of Association under item 4.3.A. The convertible loans allow Pharma Equity Group to borrow up to DKK 6,757,895. The main terms and conditions for the convertible loans are:  The loans are granted as subordinated loan capital and are thus subordinated to...

April 1, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S

Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S 25. marts 2025 Meddelelse nr. 3 Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S Bestyrelsen indkalder hermed til den ordinære generalforsamling i Pharma Equity Group A/S (“PEG” eller “Selskabet”) den: 16. april 2025, kl. 15:30 på adressen Wihlborgs KantinerSlotsmarken 152970 Hørsholm Dagsordenen for den ordinære generalforsamling er følgende: Bestyrelsens beretning om Selskabets virksomhed det forløbne årFremlæggelse af revideret årsrapport til godkendelseMeddelelse af decharge for bestyr...

March 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch